Generally, 90% occurrence is reported in adenocarcinoma of the pancreas, 50% in the colon, 30% in the lung and more specifically K-Ras mutation is prevalent in about 60% of patients with non-small-cell lung cancer [25], 50% in thyroid tumors while 30% in myeloid leukaemia. Furthermore, if we look into nephroblastoma, in spite of the lack of mutations, one of the studies suggests that the Ras pathway plays an important role in the growth and proliferation of nephroblastoma [26]. This evidence concerns the gene KRAS and Nephroblastoma.